Conversely, strong evidence indicates that SGLT-2 inhibitors have beneficial effects on major adverse cardiovascular and renal outcomes in large RCTs of people with T2DM [12,13,14,15,16]. Here, SLC5A2 is linked to type 2 diabetes mellitus.